Get the Stockscreener App
5.02
9.39%
-0.52
Nexentis Technologies Inc stock is traded at $5.02, with a volume of 6.00M.
It is down -9.39% in the last 24 hours and up +12.56% over the past month.
Nexentis Technologies Inc, is engaged in redefining mitochondrial drug discovery with help of its wholly owned biotechnology subsidiary, MitoCareX Bio focused on drug discovery company dedicated to developing first-in-class therapeutics for inflammatory metabolic diseases and cancer by targeting specific metabolic pathways. The company is also focused on sustainable operations in various industries such as solar projects, and oncology biotechnology.
See More
Previous Close:
$5.54
Open:
$5.34
24h Volume:
6.00M
Relative Volume:
224.44
Market Cap:
$3.64M
Revenue:
$2,000
Net Income/Loss:
$-12.72M
P/E Ratio:
-0.0699
EPS:
-71.8121
Net Cash Flow:
$-3.91M
1W Performance:
-0.20%
1M Performance:
+12.56%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$4.74
$5.5699
1-Week Range:
$4.45
$6.1175
52-Week Range:
$3.38
$7.56
Nexentis Technologies Inc Stock (NXTS) Company Profile
Name
Nexentis Technologies Inc
Sector
Industry
Phone
972544561349
Address
156 FIFTH AVENUE 10TH FLOOR, NEW YORK
Compare NXTS vs CTVA, NTR, CF, MOS, ICL
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NXTS
Nexentis Technologies Inc
|
4.99 | 4.05M | 2,000 | -12.72M | -3.91M | -71.81 |
CTVA
Corteva Inc
|
75.73 | 50.64B | 17.89B | 1.26B | 2.05B | 1.7029 |
NTR
Nutrien Ltd
|
65.50 | 31.74B | 27.83B | 2.42B | 2.21B | 4.9113 |
CF
Cf Industries Holdings Inc
|
105.97 | 16.42B | 7.41B | 2.12B | 1.62B | 11.13 |
MOS
Mosaic Company
|
22.37 | 7.16B | 12.05B | 575.40M | -534.60M | 1.6871 |
ICL
Icl Group Ltd
|
5.445 | 7.42B | 7.41B | 314.00M | 220.88M | 0.202 |
Nexentis Technologies Inc Stock (NXTS) Latest News
Nexentis Technologies (NXTS) sells 311,876 shares; concurrent warrants issued - Stock Titan
NXTS Q2 2025 Earnings: Loss Deepens as Pre‑Revenue Phase ContinuesGrowth Acceleration Report - newsline.com
Nexentis Technologies Announces New Equity Financing Agreements - TipRanks
Nexentis Technologies Raises $1.25 Million in Registered Direct Offering, Issues 5-Year Warrants - TradingView
Nexentis Technologies (NXTS) prices $1.25M stock and warrant offerings - Stock Titan
NXTS Q2 2025 Earnings: Loss Per Share of -$0.18 Amidst Limited Financial DisclosureProfit Announcement - newsline.com
Nexentis Technologies Inc. (NXTS) Surges 10.69% as Bullish Momentum BuildsVolatility Surface - newsline.com
NXTS Q2 2025 Earnings: Loss Per Share Widens but Stock Surges on Strategic ProgressHealthcare Earnings Report - newsline.com
NXTS News | NEXENTIS TECHNOLOGIES INC (NASDAQ:NXTS) - ChartMill
NXTS Q2 2025 Earnings: Net Loss of -$0.18 Per Share Triggers Double-Digit Stock DeclineEPS Surprise History - newsline.com
Nexentis Technologies (NXTS) Earnings Date and Reports 2026 - MarketBeat
NXTS Q2 2025 Earnings: EPS Loss Narrows, Stock Surges on Operational ProgressHealthcare Earnings Report - The Legal Advocate
Nexentis Technologies (NXTS) Surges 5.1%: Key Levels and Volume Patterns Signal Potential BreakoutCalendar Spread Trade - The Legal Advocate
Nexentis Expands Credit Facility Under Amended Financing Agreement - TipRanks
Nexentis Technologies Inc. Approves Amendment to A Facility Agreement - marketscreener.com
Nexentis Technologies (NASDAQ: NXTS) expands EUR 10M credit line and warrant terms - Stock Titan
Nexentis Technologies (NXTS) Surges 15.4% – Momentum Builds Above Key SupportAAII Bullish - newsline.com
Nexentis Technologies (NXTS) Gains 1.36% as Stock Tests Key Resistance Near $4.70Low Beta Factor - thelegaladvocate.com
Nexentis Technologies (NXTS) Earnings Outlook: Key Metrics for Q2 2025Retail Trader Picks - Newser
Nexentis subsidiary achieves drug discovery milestone By Investing.com - Investing.com South Africa
Nexentis Technologies says MitoCareX Bio achieves drug discovery milestone - TipRanks
Nexentis subsidiary reaches drug discovery milestone By Investing.com - Investing.com Nigeria
Nexentis subsidiary reaches drug discovery milestone - Investing.com
Nexentis subsidiary achieves drug discovery milestone - Investing.com
Nexentis develops new molecule to potentially tackle hard-to-treat cancers - Stock Titan
Nexentis Technologies (NASDAQ: NXTS) posts Q1 2026 loss, flags going concern risk - Stock Titan
Nexentis Technologies Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Nexentis Technologies Inc. Announces Drug Discovery Milestone Achieved by MitoCareX Utilizing MITOLINE® Platform - Quiver Quantitative
Nexentis Technologies Announces Optimization of Hit - GlobeNewswire
Nexentis Technologies Inc. (NXTS) - Zacks Investment Research
Number of shareholders of Nexentis Technologies Inc. – NASDAQ:NXTS - TradingView
Nexentis Technologies Secures US Trademark Approval for MitoCareX Algorithm Platform MITOLINE - ChemAnalyst
Nexentis Technologies stock jumps on trademark approval - Investing.com
Nexentis subsidiary receives U.S. trademark for drug platform By Investing.com - Investing.com South Africa
Nexentis Technologies stock jumps on trademark approval By Investing.com - Investing.com Nigeria
Nexentis subsidiary receives U.S. trademark for drug platform - Investing.com
Drug discovery firm secures U.S. trademark for its MITOLINE platform - Stock Titan
Nexentis Technologies Announces U.S. Trademark Registration - GlobeNewswire
NXTS (Nexentis Technologies) falls 2.62% after Q2 2025 earnings with no consensus performance benchmarks available.FCF Yield - newser.com
Nexentis Shareholders Approve Reverse Split and Financing Flexibility - The Globe and Mail
Shareholders back Nexentis (NITO) reverse split and equity financing plans - Stock Titan
[EFFECT] Nexentis Technologies Inc. SEC Filing - Stock Titan
NXTS Price History for Nexentis Technologies Stock - Barchart.com
Nexentis Technologies (NXTS) Short Interest & Short Float | Updated Apr 2026 - MarketBeat
Nexentis Technologies Inc. (NXTS) Cash Equivalents (Quarterly) - Zacks Investment Research
Nexentis Technologies Inc Stock (NXTS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.14%
4.13%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):